查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015150

神經性疼痛治療​​市場：按產品類型、給藥途徑、適應症和分銷管道分類的全球市場預測，2026-2032年

Neuropathic Pain Drug Market by Product Type, Route Of Administration, Indication, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，神經性疼痛治療​​市場價值將達到 69.3 億美元，到 2026 年將成長至 73.6 億美元，到 2032 年將達到 119.5 億美元，複合年成長率為 8.10%。

主要市場統計數據
基準年 2025 69.3億美元
預計年份：2026年 73.6億美元
預測年份 2032 119.5億美元
複合年成長率 (%) 8.10%

對神經性疼痛治療​​的多方面格局進行了權威概述，重點關注臨床複雜性、支付方壓力和不斷發展的治療選擇。

神經性疼痛是一種持續且複雜的臨床挑戰，需要不斷發展的治療模式、與監管機構的合作以及商業性上的靈活性。糖尿病神經病變、化療引起的神經病變、HIV相關神經病變和帶狀皰疹後遺症神經痛患者常出現對傳統鎮痛方法無效的慢性症狀，這促使臨床醫生和研究人員探索多方面的治療策略。近年來，臨床界在累積了屬於既定藥理分類的藥物的證據的同時，也在推動基於器械的神經調控療法和局部製劑的創新，從而拓展了治療選擇。因此，目前的處方行為反映了療效數據、耐受性特徵和監管建議之間的平衡。

我們正在策略性地整合科學突破、監管收緊和商業性重組，以重新定義治療方法開發和部署的途徑。

神經性疼痛領域正經歷一場變革，科學、安全性和系統性壓力正在改變治療方法。機制研究的進展推動著創新，使其不再局限於緩解症狀，而是轉向針對病理生理機製本身的治療方法。這包括小分子離子通道調變器、亞型選擇性鈉通道策略以及旨在調節周邊和中樞敏化的生物學方法。這種科學轉變與製劑創新相輔相成，例如高濃度局部貼片和改進的經皮給藥系統，這些創新透過提高局部療效並限制全身暴露，解決了耐受性和監管方面的擔憂。

對於治療價值鏈中的相關人員，需要對近期關稅措施如何重組供應鏈策略、採購慣例和成本控制進行嚴格評估。

美國近期推出的關稅措施給神經性疼痛藥物生態系統中的供應商、製造商和經銷商帶來了新的商業挑戰。某些進口原料和成品的成本上漲迫使採購團隊重新評估其供應商組合，並考慮近岸外包或雙重採購策略，以確保穩定的利潤率和持續的供應。依賴海外原料藥生產的公司現在必須對多個生產階段的累積成本影響進行建模，並將關稅相關的波動納入合約談判和庫存政策中。

複雜的細分分析揭示了治療領域、給藥途徑、臨床適應症和分銷管道如何決定臨床定位和商業性策略。

細分市場分析揭示了不同治療領域、給藥途徑、臨床適應症和通路的不同趨勢，這些趨勢共同決定了產品的定位和研發重點。在產品類型中，抗驚厥藥、抗憂鬱症、鴉片類藥物和外用藥物等成熟的治療領域仍然是治療流程的基礎，儘管它們的內部結構和臨床作用存在顯著差異。抗驚厥藥，如Carbamazepine、Gabapentin、拉莫三嗪和Pregabalin，在控制各種病因引起的神經性症狀方面仍然發揮核心作用。同時，以Duloxetine和去甲腎上腺素再攝取抑制劑（SNRIs）和三環抗憂鬱症（TCAs）為代表的抗憂鬱藥，在合併憂鬱症症狀或存在顯著中樞敏化的情況下，可作為主要的替代治療方法。

透過精準的區域分析，將監管特徵、支付方期望和供應鏈實際情況連結起來，制定針對特定區域的市場進入和擴大策略。

區域趨勢對監管趨勢、臨床實踐模式和供應鏈設計有顯著影響，因此每個主要區域都需要不同的策略。在美洲，醫療保健系統的特點是高度重視支付方主導的證據、療效比較以及醫療管理處方藥清單的製定流程。這些壓力促使製藥公司產生真實世界結果數據並儘早與支付方接洽。監管預期和訴訟環境也會影響風險管理策略和處方指南，尤其是在那些高度關注鴉片類藥物控制計劃和濫用預防的地區。在歐洲和中東及非洲地區（EMEA），分散的報銷體系和多樣化的監管路徑既帶來了複雜性，也為區域性價值論證提供了機會。適應性定價模式和區域性臨床證據包往往決定市場准入的時間節點。

對產業參與者的角色、夥伴關係模式和能力差距進行策略評估，這將決定誰將在差異化、創新主導的治療領域中獲勝。

神經性疼痛領域的企業格局呈現出一幅由成熟製藥公司、學名藥生產商、專業生物技術公司和合約服務供應商的複雜圖景，它們各自在為患者提供治療方法發揮著互補作用。成熟製藥公司擁有豐富的臨床試驗經驗和良好的監管記錄，能夠支持產品生命週期管理和拓展適應症；學名藥生產商則提供關鍵的准入藥物，這些藥物構成了標準治療方案的基礎。新興生物技術公司和專業研發機構正致力於研發差異化的作用機制和標靶給藥技術，旨在滿足尚未滿足的醫療需求，他們通常透過重點臨床項目和與主要合作夥伴的策略合作來實現這一目標。

一份切實可行的藍圖，包括優先策略措施和營運保障措施，旨在協調科學差異化、以支付方為中心的證據和具有彈性的供應鏈設計。

致力於在神經性疼痛領域把握機會的領導者必須採取一系列協調一致的行動，將科學差異化與商業性執行結合。首先，投資開發與機制相關的臨床項目和真實世界數據（REW），以直接滿足支付方的優先事項和患者重視的功能性終點。這將加速產品納入醫保範圍並被臨床醫生採納。其次，優先考慮價值鏈的韌性，具體措施包括：原料藥原料藥多元化、認證本地契約製造製造商以及將關稅情景規劃納入採購契約，以降低貿易政策變化帶來的風險。第三，設計強調耐受性、功能性結果和總治療成本的價值提案，並在條件允許的情況下，將這些與自適應定價和基於結果的合約相結合。

一個透明且可重複的研究框架，結合了對專家的初步訪談、嚴格的二次檢驗和情境分析，以支持策略決策。

本報告的研究採用了一種混合方法，結合了專家訪談、嚴謹的二手資料研究和檢驗。主要資訊來源包括對臨床醫生、監管專家、供應鏈高管和支付方的結構化訪談，旨在了解臨床實踐、准入障礙和採購趨勢等方面的實際觀點。這些定性資訊與監管公告、臨床試驗註冊數據、同行評審文獻和製造商資訊披露進行交叉比對，建構了將治療機制與臨床結果和安全性特徵聯繫起來的證據圖譜。

簡潔的策略整合，強調將臨床創新、以支付方為導向的證據和業務永續營運相結合的重要性，以實現永續的商業性和患者影響。

總之，神經性疼痛治療​​正處於一個轉折點，科學創新、監管環境、支付方期望和供應鏈現實相互交織，既帶來了風險，也帶來了機會。差異化的作用機制和新型製劑為滿足未被滿足的醫療需求、同時降低系統性安全隱患提供了途徑，但它們的成功取決於臨床證據的生成、與支付方的合作以及構建穩健的商業模式之間能否保持協調一致。那些整合了目標明確的臨床項目、可靠的真實世界療效、多元化的製造地和高度靈活的商業模式的機構，將更有能力創造永續的價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：神經性疼痛治療​​市場：依產品類型分類

  • 抗驚厥藥物
    • Carbamazepine
    • Gabapentin
    • 拉莫三嗪
    • Pregabalin
  • 抗憂鬱症
    • SNRI
      • Duloxetine
      • 文拉法辛
    • 三環抗憂鬱藥物（TCAs）
      • 阿米替林
      • 去甲替林
  • 鴉片類藥物
    • Tapentadol
    • 特拉馬多爾
  • 外用製劑
    • 辣椒素
    • 雙氯芬酸鈉酸凝膠
    • Lidocaine貼劑

第9章：神經性疼痛治療​​市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 外用
  • 經皮

第10章：神經性疼痛治療​​市場：依適應症分類

  • 化療引起的神經病變
  • 糖尿病神經病變
  • HIV相關神經病變
  • 帶狀皰疹後遺症神經痛

第11章：神經性疼痛治療​​市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 專科診所

第12章：神經性疼痛治療​​市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：神經性疼痛治療​​市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：神經性疼痛治療​​市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國神經性疼痛治療​​藥物市場

第16章：中國神經性疼痛治療​​藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AcelRx Therapeutics, Inc.
  • Bausch Health Companies Inc.
  • Eli Lilly and Company
  • Endo International plc
  • Grunenthal GmbH
  • Grunenthal GmbH
  • Hikma Pharmaceuticals PLC
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-036C5CF3B4DE

The Neuropathic Pain Drug Market was valued at USD 6.93 billion in 2025 and is projected to grow to USD 7.36 billion in 2026, with a CAGR of 8.10%, reaching USD 11.95 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.93 billion
Estimated Year [2026] USD 7.36 billion
Forecast Year [2032] USD 11.95 billion
CAGR (%) 8.10%

An authoritative orientation to the multifaceted neuropathic pain treatment environment stressing clinical complexity, payer pressure, and evolving therapeutic choices

Neuropathic pain presents a persistent and complex clinical challenge that demands evolving therapeutic paradigms, regulatory engagement, and commercial agility. Patients affected by diabetic neuropathy, chemotherapy-induced neuropathy, HIV-associated neuropathy, and post-herpetic neuralgia frequently experience chronic symptoms that resist conventional analgesic approaches, prompting clinicians and researchers to seek multimodal strategies. Over recent years, the clinical community has consolidated evidence for agents across established pharmacologic classes, and parallel innovations in device-based neuromodulation and topical formulations have broadened treatment options. As a result, prescribing behavior reflects a balance between efficacy data, tolerability profiles, and regulatory advisories.

Concurrently, payers and procurement teams have tightened access controls, driven by safety concerns around opioids and heightened scrutiny of gabapentinoid misuse, which together influence formulary placements and prior authorization requirements. This environment elevates the importance of differentiated value propositions and clear real-world evidence demonstrating functional and quality-of-life outcomes. Moreover, supply chain resilience and API sourcing have become strategic considerations for commercialization planning, as manufacturers re-evaluate geographic dependencies. The introduction of targeted therapies, improved formulations for topical administration, and stronger emphasis on guideline-concordant care are collectively reshaping how stakeholders prioritize clinical programs and commercial investments in the neuropathic pain domain.

A strategic synthesis of scientific breakthroughs, regulatory tightening, and commercial realignment that is redefining therapeutic development and adoption pathways

The neuropathic pain landscape is undergoing transformative shifts driven by science, safety, and system-level pressures that change how therapies are developed, adopted, and reimbursed. Mechanistic advances are steering innovation toward modalities that go beyond symptomatic relief to target pathophysiology, including small molecule ion channel modulators, subtype-selective sodium channel strategies, and biologic approaches that aim to modulate peripheral and central sensitization. This scientific pivot is complemented by formulation innovations such as high-concentration topical patches and improved transdermal delivery systems that enhance localized efficacy while limiting systemic exposure, thereby addressing tolerability and regulatory concerns.

At the same time, clinical practice is influenced by heightened regulatory scrutiny and evolving evidence standards for long-term safety, which have curtailed routine opioid reliance and prompted deeper examination of gabapentinoid adverse event profiles. These dynamics have accelerated interest in multimodal care pathways that integrate pharmacologic, device-based, and rehabilitative approaches. Commercially, stakeholders face pressure to demonstrate outcomes that matter to payers, including reduced healthcare utilization and improved patient-reported outcomes, which in turn drives investment in real-world evidence generation and adaptive pricing models. Collectively, these shifts are reconfiguring value chains and creating strategic windows for companies that align scientific differentiation with pragmatic delivery and evidence-generation plans.

A rigorous assessment of how recent tariff measures have reshaped supply chain strategies, procurement practices, and cost management for stakeholders in the therapeutic value chain

Recent tariff initiatives in the United States have introduced a new operational calculus for suppliers, manufacturers, and distributors within the neuropathic pain drug ecosystem. Elevated costs on specific imported raw materials and finished goods have pressured procurement teams to reassess supplier portfolios and to examine nearshoring or dual-sourcing strategies in order to stabilize margins and secure continuity of supply. Firms reliant on offshore API production have had to model the cumulative cost implications across multiple manufacturing tiers and to incorporate tariff-related variability into contractual negotiations and inventory policies.

These developments have also influenced pricing strategy discussions, with manufacturers evaluating whether product repositioning, formulation optimization, or greater emphasis on domestic manufacturing capacity can mitigate tariff exposure. Payers and contracting organizations have signaled sensitivity to downstream cost shifts, leading to more stringent formulary management and heightened demand for economic evidence. In response, several organizations have accelerated engagement with contract manufacturing organizations located within tariff-favorable jurisdictions and have intensified supplier qualification programs to reduce single-source dependencies. As a result, supply chain visibility, scenario planning, and proactive policy engagement have become critical capabilities for organizations aiming to maintain competitive positioning while ensuring uninterrupted patient access.

A nuanced segmentation narrative revealing how therapeutic classes, administration routes, clinical indications, and distribution channels determine clinical positioning and commercial tactics

Segmentation analysis reveals differentiated dynamics across therapeutic classes, routes of administration, clinical indications, and distribution pathways that collectively inform product positioning and development priorities. Within product type, established classes such as anticonvulsants, antidepressants, opioids, and topical agents continue to anchor treatment algorithms, but their internal composition and clinical roles differ significantly. Anticonvulsants, examined through agents such as carbamazepine, gabapentin, lamotrigine, and pregabalin, continue to be central to neuropathic symptom control in diverse etiologies, while antidepressants are represented by SNRIs and TCAs, including duloxetine, venlafaxine, amitriptyline, and nortriptyline, which serve as key alternatives where comorbid depressive symptoms or central sensitization are prominent.

Opioids, including tapentadol and tramadol, retain a focused role where benefit-risk assessments and regulatory controls permit, but their use exists within a constrained and closely monitored therapeutic window. Topical agents, with options such as capsaicin, diclofenac gel, and lidocaine patch, offer meaningful localized relief and present lower systemic safety concerns, thereby appealing to populations with polypharmacy risks. Route of administration considerations-spanning intravenous, oral, topical, and transdermal options-drive adherence, onset of action, and tolerability trade-offs, which in turn shape clinical preference and reimbursement decisions. Indication-specific nuances for chemotherapy-induced neuropathy, diabetic neuropathy, HIV-associated neuropathy, and post-herpetic neuralgia further influence clinical trial design and evidence requirements. Finally, distribution channels ranging from hospital pharmacies to retail pharmacies and specialty clinics determine access patterns, patient education opportunities, and channel-specific contracting strategies that companies must tailor to for effective commercialization.

An incisive regional assessment that connects regulatory traits, payer expectations, and supply chain realities to inform geographically specific market entry and expansion strategies

Regional dynamics exert powerful influence on regulatory trajectories, clinical practice patterns, and supply chain design, requiring tailored strategies across major geographies. In the Americas, health systems are characterized by a strong emphasis on payer-driven evidence, comparative effectiveness, and managed care formulary processes; these pressures incentivize manufacturers to generate real-world outcomes data and to engage early with payers. Regulatory expectations and litigation environments also shape risk management strategies and prescribing guidelines, particularly where opioid stewardship programs and abuse-deterrence concerns are salient. Moving to Europe, Middle East & Africa, fragmented reimbursement regimes and varied regulatory pathways create both complexity and opportunity for localized value demonstration; adaptive pricing models and region-specific clinical evidence packages often determine market access timelines.

In the Asia-Pacific region, rapid adoption of new formulations and high-volume treatment settings coexist with diverse regulatory maturity and growing domestic manufacturing capacity, which influences licensing strategies and partnership models. Supply chain considerations differ by region as well; resiliency initiatives, tariff exposure, and logistics constraints prompt distinct sourcing approaches across these geographies. Successful regional strategies therefore combine regulatory savvy, evidence generation aligned with local clinical standards, and supply chain designs that consider regional manufacturing hubs and distribution infrastructures to maintain continuity of care and optimize commercial return.

A strategic appraisal of industry participant roles, partnership models, and capability gaps that determine who wins in a differentiated and innovation-driven therapeutic landscape

Company dynamics in the neuropathic pain arena reflect a mosaic of legacy pharmaceutical firms, generics manufacturers, specialty biotechs, and contract service providers, each playing complementary roles in bringing therapies to patients. Established pharmaceutical companies maintain deep clinical trial experience and regulatory track records that support lifecycle management and label expansion efforts, while generic manufacturers supply critical access medicines that define baseline standard-of-care choices. Emerging biotechs and specialty developers are advancing differentiated mechanisms and targeted delivery technologies that aim to address unmet needs, often through focused clinical programs and strategic collaborations with larger partners.

Contract manufacturing organizations, formulation specialists, and digital therapeutics vendors have become integral to commercialization strategies, offering capabilities that enable rapid scale-up, alternative delivery formats, and supportive adherence technologies. Across the ecosystem, partnerships, licensing arrangements, and selective M&A activity have accelerated the translation of early-stage assets into clinically meaningful options. Competitive success increasingly depends on an integrated approach that aligns scientific differentiation with robust evidence-generation plans, flexible manufacturing footprints, and payer engagement strategies that emphasize patient-centered outcomes and total cost of care implications.

A pragmatic playbook of prioritized strategic moves and operational safeguards that align scientific differentiation with payer-centered evidence and resilient supply chain design

Leaders seeking to capture opportunity in the neuropathic pain domain must pursue a set of coordinated actions that bridge scientific differentiation and commercial execution. First, invest in mechanism-linked clinical programs and real-world evidence generation that directly speak to payer priorities and functional endpoints valued by patients; this will accelerate formulary acceptance and clinician uptake. Second, prioritize supply chain resilience by diversifying API sources, qualifying regional contract manufacturers, and embedding tariff scenario planning into procurement contracts to reduce exposure to trade policy shifts. Third, design value propositions that emphasize tolerability, functional outcomes, and total cost of care, and couple these with adaptive pricing and outcomes-based contracting where feasible.

Additionally, cultivate strategic partnerships with specialty clinics and hospital systems to create centers of excellence that can both validate clinical benefits and generate early real-world data. Leverage formulation innovation to offer differentiated delivery profiles, particularly topical and transdermal solutions that reduce systemic risk. Finally, align regulatory affairs, clinical development, and commercial teams early to streamline label strategy, post-approval evidence commitments, and payer engagement roadmaps that support rapid, durable uptake across heterogeneous healthcare settings.

A transparent and reproducible research framework combining expert primary interviews, rigorous secondary validation, and scenario analysis to underpin strategic decision-making

The research underpinning this dossier employed a mixed-methods approach that integrates expert primary research with rigorous secondary synthesis and validation. Primary inputs included structured interviews with clinicians, regulatory specialists, supply chain executives, and payers to capture frontline perspectives on clinical practice, access barriers, and procurement dynamics. These qualitative inputs were triangulated with regulatory announcements, clinical trial registries, peer-reviewed literature, and manufacturer disclosures to construct an evidence map linking therapeutic mechanisms to clinical outcomes and safety profiles.

Analytical methods included comparative mechanism analysis, route-of-administration impact assessment, indication-specific evidence synthesis, and supplier risk scoring to evaluate supply chain vulnerabilities. Scenario-based sensitivity testing examined the operational impact of tariff regimes and alternative sourcing strategies without relying on proprietary commercial estimates. Quality control measures included cross-validation of interview findings, independent peer review by subject matter experts, and transparent documentation of data sources and assumptions to support reproducibility and to enable stakeholders to adapt the methodology for bespoke inquiries.

A concise strategic synthesis that underscores the imperative to align clinical innovation, payer evidence, and operational resilience to realize durable commercial and patient impact

In conclusion, the neuropathic pain treatment landscape is at an inflection point where scientific innovation, regulatory dynamics, payer expectations, and supply chain realities converge to create both risk and opportunity. Differentiated mechanisms and novel formulations provide pathways to address unmet patient needs while reducing systemic safety concerns, but success depends on coherent alignment between clinical evidence generation, payer engagement, and resilient operational design. Organizations that integrate targeted clinical programs with robust real-world outcomes, diversified manufacturing footprints, and adaptive commercial models will be best positioned to deliver sustainable value.

Going forward, stakeholders should anticipate continued emphasis on outcome-based evaluation, tighter scrutiny of safety profiles for systemically acting agents, and increased preference for localized delivery solutions where appropriate. Strategic investment in localized evidence generation, regional manufacturing partnerships, and payer-centered value narratives will enable companies to navigate policy shifts and access constraints while improving patient care. The path to commercial and clinical impact will be defined by the ability to translate mechanistic promise into measurable benefits across diverse healthcare settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neuropathic Pain Drug Market, by Product Type

  • 8.1. Anticonvulsants
    • 8.1.1. Carbamazepine
    • 8.1.2. Gabapentin
    • 8.1.3. Lamotrigine
    • 8.1.4. Pregabalin
  • 8.2. Antidepressants
    • 8.2.1. SNRIs
      • 8.2.1.1. Duloxetine
      • 8.2.1.2. Venlafaxine
    • 8.2.2. TCAs
      • 8.2.2.1. Amitriptyline
      • 8.2.2.2. Nortriptyline
  • 8.3. Opioids
    • 8.3.1. Tapentadol
    • 8.3.2. Tramadol
  • 8.4. Topical Agents
    • 8.4.1. Capsaicin
    • 8.4.2. Diclofenac Gel
    • 8.4.3. Lidocaine Patch

9. Neuropathic Pain Drug Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Topical
  • 9.4. Transdermal

10. Neuropathic Pain Drug Market, by Indication

  • 10.1. Chemotherapy-Induced Neuropathy
  • 10.2. Diabetic Neuropathy
  • 10.3. HIV-Associated Neuropathy
  • 10.4. Post-Herpetic Neuralgia

11. Neuropathic Pain Drug Market, by Distribution Channel

  • 11.1. Hospitals Pharmacy
  • 11.2. Retail Pharmacies
  • 11.3. Specialty Clinics

12. Neuropathic Pain Drug Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neuropathic Pain Drug Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neuropathic Pain Drug Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Neuropathic Pain Drug Market

16. China Neuropathic Pain Drug Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AcelRx Therapeutics, Inc.
  • 17.6. Bausch Health Companies Inc.
  • 17.7. Eli Lilly and Company
  • 17.8. Endo International plc
  • 17.9. Grunenthal GmbH
  • 17.10. Grunenthal GmbH
  • 17.11. Hikma Pharmaceuticals PLC
  • 17.12. Mylan N.V.
  • 17.13. Novartis AG
  • 17.14. Pfizer Inc.
  • 17.15. Sanofi S.A.
  • 17.16. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 211. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 241. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 242. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 244. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 246. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 251. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 252. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 253. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 255. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 257. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)